Dexolve - the USP compliant SBECD• Significant solubility enhancement (10 to 100,000 fold)
• Improvement of chemical stability
• Increased bioavailability, facilitated delivery
• Reduced aggregation
• Moderate irritation or reduced side-effects
• Maximized patient safety, complete renal elimination
• Enables formulation of water-insoluble APIs in all dosage forms
• Lower API doses can be achieved
- Over 20 APIs in development using Dexolve
- Over 40 partners in commercial and development phases using Dexolve
- Research grade material available at reduced price for non-clinical development
- Flexible business model to handle partners’ requests and provide technical support on development
IN
